Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.57 |
| ▸ | PPARA | Q07869 | 10/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757418 | 0.89 | PPARA (0.45) | PPARGPPARAEPHX2 | |
| SCHEMBL6716374 | 0.89 | PPARA (0.45) | PPARGPPARAEPHX2 | |
| SCHEMBL6718052 | 0.88 | PPARA (0.51) | PPARGPPARAEPHX2 | |
| SCHEMBL5609775 | 0.86 | PPARG (0.55) | PPARGPPARAEPHX2MAOB | |
| SCHEMBL6715838 | 0.85 | PPARA (0.57) | PPARGPPARAPPARD | |
| SCHEMBL5272178 | 0.84 | PPARG (0.80) | PPARGPPARA | |
| SCHEMBL5610016 | 0.83 | PPARA (0.61) | PPARGPPARAEPHX2 | |
| SCHEMBL6716386 | 0.83 | PPARG (0.56) | PPARGPPARA | |
| SCHEMBL11361509 | 0.83 | PPARG (0.52) | PPARGPPARAEPHX2PTPN1FFAR1 | |
| SCHEMBL6715218 | 0.82 | L3MBTL1 (0.48) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | GPR119, HBB, CYP3A7 | PPARG 969/4885PPARA 1020/4885EPHX2 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.